Women's health technology is attracting more business attention, but the money is flowing to a small number of companies. Femtech startups raised $724 million in venture funding in 2025 and another $239 million in the first half of 2026, according to Dealroom figures cited by Landbase. Trackers disagree on totals, and one estimates that two companies account for nearly half of 2026 funding.
The big rounds
Midi Health announced a $100 million Series D on 3 February, led by Goodwater Capital, at a valuation above $1 billion. The company began with menopause care and says it now treats more than 25,000 patients a week, with insurance coverage reaching 45 million women, according to HLTH. It is expanding into cardiology, obesity management, autoimmune survivorship and longevity.
Midi's chief executive Joanna Strober said in the announcement that women's health had been treated like an afterthought for too long. Midi reports a 13% lower total cost of care for its patients against matched groups, according to FutureFemHealth. That is a company-reported figure, not independently verified.
Pomelo Care, a virtual provider spanning pregnancy, pediatrics and hormonal health, raised a $92 million Series C in January at a reported $1.7 billion valuation, according to Landbase and a trade summary. Dealroom lists larger rounds in September from Nua ($50 million Series C) and Evvy ($40 million Series B).
Concentration and conflicting totals
NewMarketPitch, a pitch-services firm that tracks funding, found that Midi and Pomelo together account for roughly $192 million, or 49% of the roughly $392 million of usable capital it tracked in 2026. It counted 44 deals in 2026 against 52 in 2025, a 15.4% decline, so more money is going into fewer companies.
The tallies do not match. Dealroom's first-half total of $239 million and NewMarketPitch's $392 million use different definitions, periods and sample sets. Silicon Valley Bank reported $2 billion of venture investment in women's health across the US and Europe in 2025, a broader category than femtech, according to Landbase.
Strategic and private equity interest
Established companies are also taking part. NewMarketPitch counted strategic investors in 12 of its 44 tracked deals in 2026, a 27.3% share, up from 15.4% in 2025.
The largest transaction is in diagnostics. In October 2025, Blackstone and TPG agreed to acquire Hologic for up to $18.3 billion, or $76 a share plus a contingent payment of up to $3 a share linked to breast-health revenue, according to Medion Tech's summary of Fierce Biotech reporting. A report by cancer-detection company AOA Dx found women's health startups had produced more than $100 billion in cumulative exit value since 2000, according to Healthcare Brew. The report covers data through 2024 and excludes the Hologic deal. It is a company analysis and not an audit.
Other money is arriving from outside venture. A secondary source reported that Melinda French Gates pledged $215 million to women's health in June, citing the Associated Press, and that Verdane invested in period-tracking app Clue in January.
Where the capital is going
Funding is moving from consumer apps towards clinical care and diagnostics. In NewMarketPitch's data for July 2025 to June 2026, women's primary care led with $153.5 million, or 37.2% of disclosed capital, ahead of hormonal health platforms with $117.6 million. Menstrual health tools drew only $15.1 million across three deals. The firm warns that outlier rounds drive much of the signal.
Early-stage activity points to testing and screening. In July, several startups raised capital for hormone monitoring and diagnostics, including Intu Diagnostics, Muun Health, Kāhu SiliconBio and Juno Bio, according to Everything Startups. Breast-cancer screening companies BeSound, Feminai and ScreenPoint Medical also appear in 2026 deal lists.
Risks and gaps
The sources reviewed give no reliable figure for femtech's share of overall health venture funding. Legal advisers at CMS wrote in September that women's health deals should not be treated as lifestyle or consumer-tech transactions, and that due diligence should address the issues typical of targets in the sector.
None of the sources reviewed shows that Midi, Pomelo or other leaders are profitable. Valuations of private companies come from reports and data providers, and some of the figures reached me through secondary summaries. I have not seen audited results.
What is not established
It is unclear whether the funding concentration reflects strength in a few proven models or a narrow market. Totals cannot be compared across trackers. Whether payers and employers continue to cover virtual women's care at scale is not addressed in the sources.
What to watch next
Fourth-quarter rounds will show whether investors back companies beyond the leaders. Watch whether Midi or Pomelo announce profitability, further funding or public-market plans, none of which appears in the sources reviewed. Also worth tracking are further strategic acquisitions in diagnostics and screening, and how the Hologic transaction is completed and integrated.
Nexuswild welcomes factual corrections. Email contact@nexuswild.com with evidence and the article URL.
